Article Details

J&J's Rybrevant in Combo with Lazertinib Clears Phase III in NSCLC - BioSpace

Retrieved on: 2023-09-28 20:03:05

Tags for this article:

Click the tags to see associated articles and topics

J&J's Rybrevant in Combo with Lazertinib Clears Phase III in NSCLC - BioSpace. View article details on hiswai:

Excerpt

In addition, Rybrevant also tags the EGFR- and MET-bearing cancer cells for destruction by the immune system. This approach to cancer works ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up